此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Diagnosis of Acute Rejection in Renal Transplant Patients by Urine Mass Spectrometry

2017年8月9日 更新者:Wilfried Gwinner、Hannover Medical School

Non-invasive Diagnosis of Acute Rejection in Renal Transplant Patients Using Mass Spectrometry of Urine Samples - a Multicentre Diagnostic Phase III Trial

Reliable and timely detection of acute rejections in renal transplant patients is important to preserve the graft function and to prevent premature graft failure. The current gold standard for the rejection diagnosis is a renal biopsy which is usually performed upon an unexplained decline in the graft function (determined by serum creatinine or clearance). Because of the insensitivity of creatinine determinations and the invasiveness of renal biopsies, non-invasive tests have been suggested to diagnose acute rejection including mass spectrometry (MS) analysis of urine samples.

The ability of MS analysis to detect acute rejection has been demonstrated in small studies on selected patients but evidence is lacking that this test is efficacious in the routine setting of the post-transplant patient care. Based on our previous work that established urine peptide sets for acute rejection by MS, a prospective, multicentre diagnostic phase III study will be executed.

The aim of the study is to prove that this test is as equally effective as the allograft biopsy to detect acute rejection in patients that undergo a biopsy for unexplained renal dysfunction. The perspective of this approach is that the test could be used either in place of the biopsy or as decision guidance whether a biopsy is necessary to confirm the presence of rejection. Another perspective is that the MS test (respectively, a simplified test system derived from this method) could be used in the regular post-transplant surveillance for acute rejection, in place of the relatively insensitive procedure with periodic monitoring of the graft function by creatinine determinations.

研究概览

地位

完全的

研究类型

观察性的

注册 (实际的)

600

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Aachen、德国、52074
        • RTW University of Aachen
      • Berlin、德国、10117
        • Charité Universitätsmedizin Berlin
      • Erlangen、德国、90154
        • University of Erlangen-Nuremberg
      • Essen、德国、45147
        • Universitätsklinikum Essen
      • Hannover、德国、30625
        • Hannover Medical School
      • Jena、德国、07747
        • Universitatsklinikum Jena
      • Köln、德国、51109
        • Kliniken der Stadt Koln gGmbH
      • München、德国、81377
        • Ludwig-Maximilians-Universitätsklinik München

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

概率样本

研究人群

Patients with a kidney or combined kidney/pancreas transplantation from several German transplant centres with an acute unexplained allograft dysfunction within the first year of transplantation who require a clinically indicated allograft biopsy

描述

Inclusion Criteria:

  • Adult patients with a kidney or combined kidney/pancreas transplantation
  • Unexplained renal allograft dysfunction within the first year of transplantation
  • Renal allograft biopsy, which is clinically indicated to verify or exclude an acute rejection

Exclusion Criteria:

  • Lacking consent of the patient to participate in the study

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Ability of the urine mass spectrometry test to diagnose acute renal allograft rejection, compared to the gold standard 'allograft biopsy'
大体时间:Results of the urine test will be assessed in relation to the simultaneously performed allograft biopsy (1 day)

In patients with unexplained renal allograft dysfunction who get an allograft biopsy to clarify if an acute rejection is present, a simultaneous urine sample will be taken.

The peptide pattern of this urine sample is analyzed by mass spectrometry and a diagnosis is made (rejection present/not present) based on a pre-defined peptide pattern which was established to detect acute allograft rejection.

In the primary outcome analysis, the sensitivity and specificity of the rejection diagnosis by the urine test is compared to the diagnosis made by the allograft biopsy.

Results of the urine test will be assessed in relation to the simultaneously performed allograft biopsy (1 day)

次要结果测量

结果测量
措施说明
大体时间
Sensitivity and specificity of the urine test to diagnose acute renal allograft rejection in subgroups with different severity grades of the rejection
大体时间:Results of the urine test will be assessed in relation to the simultaneously performed allograft biopsy (1 day)
Sensitivity/specificity measures for the urine test will be determined in subgroups of patients with different severity of the rejection. Severity grading is based on the pathomorphological classification of the rejection (according to the BANFF classification) and on the functional impairment of the allograft at the time of rejection diagnosis.
Results of the urine test will be assessed in relation to the simultaneously performed allograft biopsy (1 day)
Sensitivity and specificity of the urine test to diagnose acute renal allograft rejection in subgroups with kidney transplantation alone and with combined pancreas/kidney transplantation
大体时间:Results of the urine test will be assessed in relation to the simultaneously performed allograft biopsy (1 day)
Sensitivity/specificity measures for the urine test will be determined in subgroups of patients who have a kidney transplant or a combined pancreas/kidney transplant.
Results of the urine test will be assessed in relation to the simultaneously performed allograft biopsy (1 day)
Sensitivity and specificity of the urine test to diagnose acute renal allograft rejection in subgroups with concurrent infection
大体时间:Results of the urine test will be assessed in relation to the simultaneously performed allograft biopsy (1 day)
Sensitivity/specificity measures for the urine test will be determined in subgroups of patients who have concurrent infections at the time of the biopsy and urine sampling such as cytomegaly virus, polyoma virus, and urinary tract infection. The analysis intends to identify potential interference of these conditions with the urine mass spectrometry test.
Results of the urine test will be assessed in relation to the simultaneously performed allograft biopsy (1 day)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Wilfried Gwinner, Prof. /MD、Hannover Medical School

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2011年10月1日

初级完成 (实际的)

2017年3月1日

研究完成 (实际的)

2017年6月15日

研究注册日期

首次提交

2011年3月14日

首先提交符合 QC 标准的

2011年3月14日

首次发布 (估计)

2011年3月15日

研究记录更新

最后更新发布 (实际的)

2017年8月10日

上次提交的符合 QC 标准的更新

2017年8月9日

最后验证

2017年8月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • MS-GW4/6-1

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅